Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: Ex-vivo permeation and in-vivo pharmacokinetic studies

Pharmaceutical Research

Volumn 26, Issue 11, 2009, Pages 2446-2453

  Elshafeey, Ahmed H ^a   Kamel, Amany O ^b   Fathallah, Mohsen M ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b Ain Shams University   (Egypt)

^c Genuine Research Center   (Egypt)

Author keywords

LC MS MS; Microemulsion; Pharmacokinetics; Tolterodine tartrate; Transdermal

Indexed keywords

ACETIC ACID ETHYL ESTER; DIETHYLENE GLYCOL MONOETHYL ETHER; EMULSIFYING AGENT; LABRASOL; MACROGOL 400; MYRISTIC ACID ISOPROPYL ESTER; NANOPARTICLE; OLEIC ACID; PHOSPHATE; PLUROL; POLYGLYCEROL DIISOSTEARIC ACID; TOLTERODINE; UNCLASSIFIED DRUG; WATER; WATER OIL CREAM;

ABSENCE OF SIDE EFFECTS; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; EX VIVO STUDY; HUMAN; IN VIVO STUDY; LIQUID; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MINIPIG; NONHUMAN; NORMAL HUMAN; PARTICLE SIZE; PH; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN PERMEABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCOSITY;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; BENZHYDRYL COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRESOLS; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; MALE; NANOPARTICLES; PERMEABILITY; PHENYLPROPANOLAMINE; SKIN; SOLVENTS; SWINE; VISCOSITY;

EID: 70350238641     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-9956-5     Document Type: Article

References (34)

1. P Abrams L Cardozo M Fall D Griffiths P Rosier U Ulmsten P Van Kerrebroeck A Victor A Wein 2003 The standardisation of terminology in lower urinary tract function: Report from the standardisation subcommittee of the International Continence Society Urology. 61 37 49 10.1016/S0090-4295(02)02243-4 12559262 (Pubitemid 36151708)
2. WF Stewart JB Van Rooyen GW Cundiff 2003 Prevalence and burden of overactive bladder in the United States World J Urol 20 327 36 1:STN:280:DC%2BD3s3osVWkuw%3D%3D 12811491
3. SJ Berry DS Coffey PC Walsh LL Ewing 1984 The development of human benign prostatic hyperplasia with age J Urol 132 474 9 1:STN:280:DyaL2c3pt1CrtQ%3D%3D 6206240
4. DE Irwin I Milsom Z Kopp 2006 Impact of overactive bladder symptoms on employment, social interactions and emotional wellbeing in six European countries BJU Int. 97 96 100 10.1111/j.1464-410X.2005.05889.x 16336336
5. SA Kaplan CG Roehrborn R Dmochowski 2006 Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia Urology. 68 328 32 10.1016/j.urology.2006.03.006 16904446 (Pubitemid 44175507)
6. YF Yu MB Nichol AP Yu J Ahn 2005 Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program Value Health. 8 495 505 10.1111/j.1524-4733.2005.00041.x 16091027
7. J Malone-Lee B Shaffu C Anand C Powell 2001 Tolterodine superior tolerability and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial J Urol. 165 1452 6 10.1016/S0022-5347(05)66326-4 1:CAS:528:DC%2BD3MXjvVaitLc%3D 11342895
8. SR Serels RA Appell 1999 Tolterodine: a new antimuscarinic agent for the treatment of the overactive bladder Expert Opin Investig Drugs. 8 7 1073 8 10.1517/13543784.8.7.1073 1:CAS:528:DyaK1MXktlOltr8%3D 15992107 (Pubitemid 29329039)
9. N Brynne MM Stahl B Hallen PO Edlund L Palmer P Hoglund J Gabrielsson 1997 Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity Int J Clin Pharmacol Ther. 35 7 287 95 1:CAS:528:DyaK2sXkslyqsb4%3D 9247842
10. MMA Elsayed OY Abdallah VF Naggar NM Khalafallah 2007 Lipid vesicles for skin delivery of drugs: reviewing three decades of research Int. J. Pharm. 332 1 16 10.1016/j.ijpharm.2006.12.005 1:CAS:528:DC%2BD2sXhvVSlu74%3D 17222523 (Pubitemid 46237706)
11. A Kogan N Garti 2006 Microemulsions as transdermal drug delivery vehicles Adv. Colloid Interface Sci. 123-126 369 385 10.1016/j.cis.2006.05.014 16843424 (Pubitemid 44665819)
12. M Kreilgaard MJ Kemme J Burggraaf RC Schoemaker AF Cohen 2001 Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics Pharm Res. 18 5 593 9 10.1023/A:1011068907416 1:CAS:528:DC%2BD3MXltVKmt7Y%3D 11465413 (Pubitemid 32595786)
13. AC Sintov S Botner 2006 Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems Int J Pharm. 311 1-2 55 62 10.1016/j.ijpharm.2005.12.019 1:CAS:528:DC%2BD28XhvF2lsL8%3D 16431047 (Pubitemid 43319202)
14. P Spiclin M Homar A Zupancic-Valant M Gasperlin 2003 Sodium ascorbyl phosphate in topical microemulsions Int J Pharm. 256 1-2 65 73 10.1016/S0378-5173(03)00063-2 1:CAS:528:DC%2BD3sXivVGjsbs%3D 12695012 (Pubitemid 36412140)
15. VP Shah KK Midha S Dighe IJ McGilveray JP Skelly A Yacobi T Layloff CT Viswanathan CE Cook RD McDowall 1991 Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies Conference report. Eur J Drug Metab Pharmacokinet. 16 4 249 55 1:STN:280:DyaK38zoslWktA%3D%3D
16. MJ Alvarez-Figueroa J Blanco-Mendez 2001 Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions Int. J. Pharm. 215 1-2 57 65 10.1016/S0378-5173(00)00674-8 1:CAS:528:DC%2BD3MXhsleltb4%3D 11250092 (Pubitemid 32206604)
17. B Godin E Touitou 2007 Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models Adv Drug Deliv Rev 59 11 1152 61 10.1016/j.addr.2007.07.004 1:CAS:528:DC%2BD2sXht1amsL7J 17889400 (Pubitemid 47615204)
18. ''Declaration of Helsinki.'' As amended by the 52nd World Medical Assembly (WMA). World Medical Association, Edinburgh, Scotland, October 2000.
19. International conference of harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline. Guidelines for good clinical practice. May 1996.
20. B Ongpipattanakul RR Burnette RO Potts ML Francoeur 1991 Evidence that oleic acid exists in a separate phase within stratum corneum lipids Pharm. Res. 8 350 354 10.1023/A:1015845632280 1:CAS:528:DyaK3MXitFChtbo%3D 2052523
21. J Hadgraft 1999 Passive enhancement strategies in topical and transdermal drug delivery Int J. of Pharm. 184 1 6 1:CAS:528:DyaK1MXks1CqtLY%3D
22. P Mayorga F Puisieux G Couarraze 1996 Formulation study of a transdermal delivery system of primaquine Int. J. Pharm. 132 71 79 10.1016/0378-5173(95) 04348-9 1:CAS:528:DyaK28XjtFSksbs%3D (Pubitemid 26160305)
23. XS Zheng CZ Duan ZD Xiao BA Yao 2008 Transdermal delivery of praziquantel: effects of solvents on permeation across rabbit skin Biol Pharm Bull. 31 5 1045 8 10.1248/bpb.31.1045 1:CAS:528:DC%2BD1cXotF2mtbY%3D 18451545 (Pubitemid 351732010)
24. BJ Thomas BC Finnin 2004 The transdermal revolution. Drug Discov. Today. 9 16 697 703 10.1016/S1359-6446(04)03180-0 1:CAS:528:DC%2BD2cXmsVCqtLs%3D (Pubitemid 39070282)
25. A Fini V Bergamante GC Ceschel C Ronchi CA De Moraes 2008 Control of transdermal permeation of hydrocortisone acetate from hydrophilic and lipophilic formulations AAPS PharmSciTech. 9 3 762 8 10.1208/s12249-008-9107-z 18563577
26. Menon G.K. New insights into skin structure: scratching the surface. Adv Drug Deliv Rev. 54 (1): S3-17(2002).
27. K Klamerus G Lee 1992 Effects of some hydrophilic permeation enhancers on the absorption of bepridil through excised human skin Drug Dev. and Ind. Pharmacy. 18 13 1411 1422 10.3109/03639049209040848 1:CAS:528:DyaK38XkvFOhsrs%3D
28. M. Kreilgaard, E.J. Pedersen, J.W. Jaroszewski. NMR. characterisation and transdermal drug delivery potential of microemulsion systems. J. Control Rel. 69:421-433 (2000).
29. H. E. J. Hofland, J. A. Bouwstra, F. Spies, G. Gooris, H. E. Junginger. Interaction between liposomes and human skin in vitro: Poster presentation. Conference: Liposomes in Drug Delivery 21 years On, London, 12-15 (1990).
30. N. Weiner, K. Egbaria. Topical application of liposomal systems: Poster presentation. Conference: Liposomes in Drug Delivery 21 years On, London, 12-15 (1990).
31. JH Kweon SC Chi ES Park Transdermal 2004 delivery of diclofenac using microemulsions Arch Pharm Res. 27 3 351 6 10.1007/BF02980072 1:CAS:528:DC%2BD2cXivFCmtbg%3D 15089043 (Pubitemid 43073760)
32. MB Delgado-Charro G Iglesias-Vilas J Blanco-Mendez MA Lopez-Quintela JP Marty RH Guy 1997 Delivery of a hydrophilic solute through the skin from novel microemulsion systems Eur. J. Pharm. Biopharm. 43 37 42 10.1016/S0939-6411(96) 00016-1 (Pubitemid 28298808)
33. B Olsson J Szamosi 2001 Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine Clin Pharmacokinet. 40 3 227 35 10.2165/00003088-200140030-00006 1:CAS:528:DC%2BD3MXjsVWmtrc%3D 11327200
34. Guay D.R.P. Clinical Pharmacokinetics of Drugs Used to Treat Urge Incontinence Clin Pharmacokinet. 42(14): 1243-1285 (2003).